BioSpace News Archive

OSSIO, Inc., a fast-growing orthopedic fixation technology company, on Friday received “breaking” news from the U.S. Food and Drug Administration (FDA).

Apellis Pharmaceuticals, Inc., announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

LianBio (NASDAQ: LIAN) today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs (the “Proposal”).

Wave Life Sciences Ltd. (Nasdaq: WVE) today announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 as a potential treatment for alpha-1 antitrypsin deficiency (AATD).

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors.

89bio, Inc. announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

The PumasAI Board of Directors are pleased to announce that, effective January 1, 2024, Dr. Vijay Ivaturi will be stepping into the role of Chief Executive Officer, succeeding Dr. Joga Gobburu. After four years of dedicated leadership, Dr. Gobburu will be transitioning from his current role as CEO to the position of Chairman of the Board of PumasAI.

TeraPore Technologies, an innovator in nanofiltration membranes, has commercially launched the flagship IsoBlock® VF product line for parvovirus removal from biopharmaceuticals.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple negative breast cancer (TNBC). Results will be presented today at the 2023 San Antonio Breast Cancer Symposium® (SABCS).

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine.